Is Orphan saving Biotech?

Orphan drugs have been en vogue for a while. However, in the last quarter there has been a record financing that has put drugs for small patient populations on the map even more. In Q1 2014, over 60% of the financing in European Biotech has gone to companies that have a lead orphan drug product. … Continue reading Is Orphan saving Biotech?

Read more

What is the impact of Novartis transformation on biotech industry?

With the announcement of the portfolio transformation of Novartis this month, we believe this will have a positive impact on the biotech industry. The company will focus on Pharmaceuticals, Eye Care and Generics. The diversification strategy of former CEO and Chairman Daniel Vasella has been axed by the new leadership of Novartis. Key components of … Continue reading What is the impact of Novartis transformation on biotech industry?

Read more